Lurasidone is approved for schizophrenia and bipolar depression on the strength of acute trials that mostly reported a single number: the change in PANSS total score. A 2026 post-hoc analysis of the JEWEL Phase 3 trial pulls that number apart, looking separately at five symptom domains and at all 30 individual items of the PANSS …
Obsessive-compulsive disorder (OCD), a prevalent neuropsychiatric condition, presents significant treatment challenges due to its varied symptom patterns and poor response to traditional medications. Recent research has revealed a novel approach to treating OCD, focusing on the interplay between dopamine D2 receptor (D2R) agonists and proton pump inhibitors (PPIs). Highlights: OCD’s Complex Treatment Landscape: Traditional treatments …
Reglan (Metoclopramide) is a medication approved by the FDA for the treatment of gastroparesis or delayed stomach emptying. Gastroparesis often occurs as a result of conditions such as GERD (gastroesophageal reflux disease) and diabetes, but is also sometimes experienced by patients following surgery (post-operative). Assuming an individual postpones treatment of ongoing gastroparesis, stomach acid can …
Vraylar (Cariprazine) was approved by the FDA on September 17, 2015 for the treatment of schizophrenia and mania associated with bipolar disorder. In clinical trials, the drug was referenced as “RGH-188” – containing Cariprazine as the primary active ingredient. The drug had completed Phase III clinical trials in 2012, and was pending FDA approval for …